These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 17983557

  • 1. PPAR agonists and the metabolic syndrome.
    Staels B.
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [Abstract] [Full Text] [Related]

  • 2. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ.
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [Abstract] [Full Text] [Related]

  • 3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A.
    Acta Med Indones; 2006 Sep; 38(3):160-6. PubMed ID: 17119268
    [Abstract] [Full Text] [Related]

  • 4. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [Abstract] [Full Text] [Related]

  • 5. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 6. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA, Nicholls SJ, Lincoff AM.
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [Abstract] [Full Text] [Related]

  • 7. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 May; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 8. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y.
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 11. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE.
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [Abstract] [Full Text] [Related]

  • 12. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G, Staels B.
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [Abstract] [Full Text] [Related]

  • 13. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M.
    Prog Mol Biol Transl Sci; 2014 Nov; 121():217-66. PubMed ID: 24373239
    [Abstract] [Full Text] [Related]

  • 14. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Dec; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD, Plutzky J.
    Circulation; 2007 Jan 30; 115(4):518-33. PubMed ID: 17261671
    [Abstract] [Full Text] [Related]

  • 17. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD.
    Ann N Y Acad Sci; 2006 Nov 30; 1083():306-18. PubMed ID: 17148746
    [Abstract] [Full Text] [Related]

  • 18. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct 30; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 19. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun 30; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

  • 20. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.